Presentation (CTI)

OBJECTIVES: This study sought to estimate the poly (ADP-ribose) polymerase (PARP) inhibitor-eligible population and associated market opportunity across EU15 countries, stratified by tumour type (ovarian, breast, and prostate cancer), line of therapy, and geography.
METHODS: A descriptive epidemiological and market sizing analysis was conducted in advanced-stage ovarian, breast, and prostate cancer (including metastatic and recurrent disease), integrating published incidence data with treatment and market share assumptions. Patient flow models captured progression from diagnosis through staging and treatment lines. Populations were stratified into non-metastatic and metastatic disease, with further segmentation into drug-treatable and drug-treated groups by line of therapy. Country-level incidence data across EU15 were combined with stage- and line-specific patient flows to estimate eligible populations. Treatment rates and PARP inhibitor market share assumptions were applied to estimate treated populations and associated market opportunity.
RESULTS: Patient flow modelling estimated the PARP inhibitor-eligible population across EU15, segmented by tumour type, line of therapy, and geography. Differences in progression to advanced disease were observed across tumour types, influencing utilisation patterns. Recurrence-driven pathways were more prominent in ovarian cancer compared with breast cancer, with earlier detection shaping treatment trajectories. The analysis enabled cross-indication comparison and estimation of the total addressable market and associated financial value of PARP inhibitors across EU15.
CONCLUSIONS: This EU-wide, cross-indication assessment provides a unified framework to quantify PARP inhibitor-eligible populations and associated market opportunity across key tumour types. These findings offer a structured basis for cross-indication prioritisation and may support evidence-based planning and market access decision-making in oncology.